Preclinical Evaluation of TB/FLU-04L—An Intranasal Influenza Vector-Based Boost Vaccine against Tuberculosis
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24087439 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Anna-Polina Shurygina und 11 weiteren Autor:innen. Beteiligte Einrichtung: Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation, 197022 St. Petersburg, Russia. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, Tuberculosis, Mycobacterium tuberculosis. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan.
Abstract (Originalsprache)
Tuberculosis is a major global threat to human health. Since the widely used BCG vaccine is poorly effective in adults, there is a demand for the development of a new type of boost tuberculosis vaccine. We designed a novel intranasal tuberculosis vaccine candidate, TB/FLU-04L, which is based on an attenuated influenza A virus vector encoding two mycobacterium antigens, Ag85A and ESAT-6. As tuberculosis is an airborne disease, the ability to induce mucosal immunity is one of the potential advantages of influenza vectors. Sequences of ESAT-6 and Ag85A antigens were inserted into the NS1 open reading frame of the influenza A virus to replace the deleted carboxyl part of the NS1 protein. The vector expressing chimeric NS1 protein appeared to be genetically stable and replication-deficient in mice and non-human primates. Intranasal immunization of C57BL/6 mice or cynomolgus macaques with the TB/FLU-04L vaccine candidate induced Mtb-specific Th1 immune response. Single TB/FLU-04L immunization in mice showed commensurate levels of protection in comparison to BCG and significantly increased the protective effect of BCG when applied in a “prime-boost” scheme. Our findings show that intranasal immunization with the TB/FLU-04L vaccine, which carries two mycobacterium antigens, is safe, and induces a protective immune response against virulent M. tuberculosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Smorodintsev Research Institute of Influenza of the Ministry of Health of the Russian Federation, 197022 St. Petersburg, Russia.
- Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Health of the Russian Federation, 191036 St. Petersburg, Russia.
- Research Institute for Biological Safety Problems, Gvardeiskiy 080409, Kazakhstan.
ORCID-Profile: Anna-Polina Shurygina, Gulbanu Sarsenbayeva
Förderung
- Science Committee of the Ministry of Education and Science of the Republic of Kazakhstan
Zitieren
APA
Shurygina, A. P., Zabolotnykh, N., Vinogradova, T., Khairullin, B., Kassenov, M., Nurpeisova, A., Sarsenbayeva, G., Sansyzbay, A., Vasilyev, K., Buzitskaya, J., Egorov, A., & Stukova, M. (2023). Preclinical Evaluation of TB/FLU-04L—An Intranasal Influenza Vector-Based Boost Vaccine against Tuberculosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24087439
Vancouver
Shurygina AP, Zabolotnykh N, Vinogradova T, Khairullin B, Kassenov M, Nurpeisova A, et al. Preclinical Evaluation of TB/FLU-04L—An Intranasal Influenza Vector-Based Boost Vaccine against Tuberculosis. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24087439
BibTeX
@article{Shurygina2023,
author = {Shurygina, Anna-Polina and Zabolotnykh, Natalia and Vinogradova, Tatiana and Khairullin, Berik and Kassenov, Markhabat and Nurpeisova, Ainur and Sarsenbayeva, Gulbanu and Sansyzbay, Abylai and Vasilyev, Kirill and Buzitskaya, Janna and Egorov, Andrey and Stukova, Marina},
title = {Preclinical Evaluation of TB/FLU-04L—An Intranasal Influenza Vector-Based Boost Vaccine against Tuberculosis},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24087439}
}
EUVIMED